Preclinical Oncology Articles & Analysis
10 news found
Mulinacci added, “I look forward to working with the team at Araris to expand on its business development efforts as they further advance their oncology pipeline of next-generation antibody-drug conjugates (ADCs) into the clinic. ...
Novartis obtains exclusive worldwide rights for pre-clinical inhibitors of a novel cancer target MorphoSys receives an upfront payment of $23 million, potential milestone payments, plus mid-single- to low-double-digit royalties on net sales MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has entered into a global ...
Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. ...
Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" - IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 - ...
Aim for IPO, in the 4Q of 2022 through Unicorn special track Clinical trial data from the phase 1/2 study of GI-101 monotherapy and combination therapy with Keytruda of GI-101 and phase 1 study of GI-301 to be released by end of 2022 GI Innovation, Inc., an innovative new drug development company announced its submission of a preliminary application for KOSDAQ listing on April 20th. The ...
Highlights Five conference abstracts will be presented as poster presentations at AACR in the immuno-oncology and preclinical immunotherapy sessions Four presentations describe preclinical data from Carina’s LGR5-targeted CAR-T cell program, one poster will describe preclinical data from Carina’s ADAM-10 CAR-T ...
INOVOTION’s high-value preclinical oncology assay quickly identifies your most effective anticancer drug candidates. ...
He was also Chairman of the Novartis Oncology Portfolio Management Board. Dr Filipovic obtained his PhD in Biochemistry and Biophysics from the Swiss Federal Institute of Technology (ETH) in Zürich. ...
Biopticon Corporation Announces the release of the new version of their innovative TumorManagerTM Program for managing pre-clinical oncology study data Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today released the latest version of their TumorManagerTM Program (version 1.3). It will be ...
Biopticon Corporation reaches milestone in market adoption of their innovative Tumor Management System for preclinical oncology studies. Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today announced that it had met its first milestone for customer adoption ...